Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Bridging in CAR-T for R/R B-NHL
NCT06695013Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in B-cell non-Hodgkin lymphoma, sponsored by Ruijin Hospital. Started Nov 2024; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06695013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06695013.